Trials / Completed
CompletedNCT00734045
Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (estimated)
- Sponsor
- Nanogen, Inc. · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to establish the correlation between NT-proBNP measurements in fresh human whole blood samples and those in plasma samples from the same study subjects, where said samples are collected in EDTA and Li-Hep anticoagulant tubes and measured by the StatusFirst™ CHF NT-proBNP device in conjunction with the DXpressTM Reader in a laboratory setting.
Conditions
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-08-13
- Last updated
- 2008-12-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00734045. Inclusion in this directory is not an endorsement.